Abstract
High blood pressure (BP) along with smoking habit and lipid disorders are the most important and modifiable risk factors for cardiovascular diseases. However, the prevalence of high BP has grown progressively over time with a progressive increase not only in the absolute number of patients but in the proportion of those showing BP values out of control. The increasing world-wide prevalence of hypertension and the related increase in burden of the disease due to diagnosis, treatment and management of the complications mandates both Health Authorities and research institutions to find out new strategies to improve the BP control. So, one of the main questions is which are the possible perspectives for the future of high BP management, and in particular how can we face the problem of hypertension in the near future? Four main points will be shortly discussed: the genetic contribution to hypertension development and control, the availability of effective preventive strategies, the improvement of disease management, and the role of extensive control of concomitant risk factors. It is relatively easy to suppose that the integration of the best available knowledge with the more recent diagnostic and therapeutic achievements will improve the management of hypertension through a more effective detection of subjects at risk who will undergo an earlier diagnosis leading to a more tailored, tolerated and effective treatment of the hypertensive disease. This means that the future direction of the hypertension management is the simpler: the patient instead of the disease.
Keywords: Blood pressure, diagnosis, hypertension, management, perspectives, therapeutics
Current Vascular Pharmacology
Title:Hypertension: Quo Vadis?
Volume: 10 Issue: 6
Author(s): Claudio Borghi
Affiliation:
Keywords: Blood pressure, diagnosis, hypertension, management, perspectives, therapeutics
Abstract: High blood pressure (BP) along with smoking habit and lipid disorders are the most important and modifiable risk factors for cardiovascular diseases. However, the prevalence of high BP has grown progressively over time with a progressive increase not only in the absolute number of patients but in the proportion of those showing BP values out of control. The increasing world-wide prevalence of hypertension and the related increase in burden of the disease due to diagnosis, treatment and management of the complications mandates both Health Authorities and research institutions to find out new strategies to improve the BP control. So, one of the main questions is which are the possible perspectives for the future of high BP management, and in particular how can we face the problem of hypertension in the near future? Four main points will be shortly discussed: the genetic contribution to hypertension development and control, the availability of effective preventive strategies, the improvement of disease management, and the role of extensive control of concomitant risk factors. It is relatively easy to suppose that the integration of the best available knowledge with the more recent diagnostic and therapeutic achievements will improve the management of hypertension through a more effective detection of subjects at risk who will undergo an earlier diagnosis leading to a more tailored, tolerated and effective treatment of the hypertensive disease. This means that the future direction of the hypertension management is the simpler: the patient instead of the disease.
Export Options
About this article
Cite this article as:
Borghi Claudio, Hypertension: Quo Vadis?, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520927
DOI https://dx.doi.org/10.2174/157016112803520927 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PDE5 Inhibitors in the Treatment of LUTS
Current Pharmaceutical Design Warming Up to New Possibilities with the Capsaicin Receptor TRPV1: mTOR, AMPK, and Erythropoietin
Current Neurovascular Research Repurposing of Existing Drugs for the Bacterial Infections: An In silico and In vitro Study
Infectious Disorders - Drug Targets The Cardiorenal Syndrome: Pathophysiologic Crosstalk, Outcomes, and Treatment Targets
Cardiovascular & Hematological Disorders-Drug Targets Mediterranean Diet and Longevity
Current Nutrition & Food Science Influence of Statin Use on Endothelial Function: From Bench to Clinics
Current Pharmaceutical Design Molecular Pathophysiology of Renal Tubular Acidosis
Current Genomics OPA1 in Cardiovascular Health and Disease
Current Drug Targets Determination of the Percent Composition and Mineral Content of the Leaves of the Insulin Plant (Cissus sicyoides) with the Goal of Including it in the Usual Diet
The Natural Products Journal Low-dose Tissue Plasminogen Activator is as Effective as Standard Tissue Plasminogen Activator Administration for the Treatment of Acute Ischemic Stroke
Current Neurovascular Research Oxidative Stress and Transforming Growth Factor-β<sub>1</sub>-induced Cardiac Fibrosis
Cardiovascular & Hematological Disorders-Drug Targets Editorial: Understanding Basic Muscle Electrophysiology While Keeping an Eye on Diseases of the Heart, Lung and Blood
Recent Patents on Cardiovascular Drug Discovery The Role of Intracellular 35-Cyclic Adenosine Monophosphate (cAMP) in Atherosclerosis
Current Vascular Pharmacology Matrix Metalloproteinases and Colon Anastomosis Repair: A New Indication for Pharmacological Inhibition?
Mini-Reviews in Medicinal Chemistry Atheromatosis Extent in Coronary Artery Disease is not Correlated with Apolipoprotein-E Polymorphism and its Plasma Levels, but Associated with Cognitive Decline
Current Alzheimer Research VEGF, a Mediator of the Effect of Experience on Hippocampal Neurogenesis
Current Alzheimer Research Angiotensin II Type 1 and Type 2 Receptor-induced Cell Signaling
Current Pharmaceutical Design Role of Hydrogen Sulfide in Systemic and Pulmonary Hypertension: Cellular Mechanisms and Therapeutic Implications
Cardiovascular & Hematological Agents in Medicinal Chemistry Subject Index to Volume 5
Current Drug Metabolism Anthropometric Correlation with Metabolic Syndrome in Sarajevo Population
Endocrine, Metabolic & Immune Disorders - Drug Targets